Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 1Lung Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignancies 1Adenocarcinoma 1

Interventions

Nivolumab 7cabozantinib 5Specimen Handling 5Ipilimumab 5CTLA-4 Antigen 4Magnetic Resonance Spectroscopy 2sodium-iodide symporter 1sitravatinib 1lenvatinib 1fludarabine 1Zoledronic Acid 1Tissue Banks 1Radiotherapy 1Radiopharmaceuticals 1Pluvicto 1Ibandronic Acid 1Everolimus 1Diphosphonates 1Denosumab 1Blood Specimen Collection 1Biopsy 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × sitravatinib × 90 days × Clear all
NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡